中国肺癌杂志2025，Vol.28Issue(8)：612-620,9.DOI:10.3779/j.issn.1009-3419.2025.106.22
HER2突变晚期非小细胞肺癌的靶向治疗进展
Advances in Targeted Therapy for Advanced Non-small Cell Lung Cancer with HER2 Mutation
摘要
Abstract
Human epidermal growth factor receptor 2(HER2)mutations play a role as a driver gene in non-small cell lung cancer(NSCLC).Patients with advanced NSCLC harboring HER2 mutations exhibit poor responses to conventional chemotherapy and immunotherapy,hence targeted therapies against HER2 are under extensive investigation.This review analyzes the biological characteristics of HER2,an overview of clinical trials for targeted therapy drugs,including monoclo-nal antibodies,tyrosine kinase inhibitors(TKIs),and antibody-drug conjugate,and research directions for drug resistance in NSCLC.Currently,Pyrotinib and Trastuzumab deruxtecan have been approved for the treatment of advanced NSCLC with HER2 mutations,suitable for patients who have failed standard therapy,which is far from meeting the clinical demands.Novel selective HER2 TKIs are gradually emerging.Future exploration trends are gradually shifting from single drugs to combination strategies,and are exploring more precise selection strategies as well as research on resistance mechanisms.These studies will provide a theoretical basis for clinical treatment strategies for advanced NSCLC with HER2 mutations,promoting the develop-ment of personalized therapy.关键词
肺肿瘤/人类表皮生长因子受体2/突变/靶向治疗Key words
Lung neoplasms/Human epidermal growth factor receptor 2/Mutation/Targeted therapy引用本文复制引用
于金玉,曹宝山..HER2突变晚期非小细胞肺癌的靶向治疗进展[J].中国肺癌杂志,2025,28(8):612-620,9.基金项目
This paper was supported by the grant from Beijing Xisike Clinical Oncology Research Foundation(No.Y-2022HER2AZMS-0361)(to Baoshan CAO). 本文受北京市希思科临床肿瘤学研究基金会项目(No.Y-2022HER2AZMS-0361)资助 （No.Y-2022HER2AZMS-0361）
